We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$68.5B
AUM Growth
-$9.16B
Cap. Flow
+$4.06B
Cap. Flow %
5.93%
Top 10 Hldgs %
21.45%
Holding
3,375
New
359
Increased
2,434
Reduced
285
Closed
282

Top Buys

Rank Stock Value
1
LIN icon
Linde
LIN
+$124M
2
AAPL icon
Apple
AAPL
+$110M
3
MSFT icon
Microsoft
MSFT
+$104M
4
AMZN icon
Amazon
AMZN
+$71.3M
5
WBD icon
Warner Bros
WBD
+$69.6M

Top Sells

Rank Stock Value
1
T icon
AT&T
T
+$61.6M
2
CERN
Cerner Corp
CERN
+$50.9M
3
NXPI icon
NXP Semiconductors
NXPI
+$31.4M
4
AZPN
ASPEN TECHNOLOGY INC
AZPN
+$30.4M
5
YUMC icon
Yum China
YUMC
+$16.3M

Sector Composition

Rank Sector Weight
1 Technology 23.13%
2 Healthcare 14.42%
3 Financials 13.45%
4 Consumer Discretionary 10.49%
5 Industrials 9.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ZVRA icon
3251
Zevra Therapeutics
ZVRA
$622M
-32,381
Closed -$163K
LENZ
3252
LENZ Therapeutics
LENZ
$165M
-3,523
Closed -$126K
QTTB icon
3253
Q32 Bio
QTTB
$490M
-3,151
Closed -$172K
RPT
3254
Rithm Property Trust
RPT
$95.4M
-4,396
Closed -$309K
TECX
3255
Tectonic Therapeutic
TECX
$558M
-3,882
Closed -$61K
NAGE
3256
Niagen Bioscience
NAGE
$236M
-47,049
Closed -$116K
VOXX
3257
DELISTED
VOXX International Corporation Class A
VOXX
-18,979
Closed -$189K
SYRS
3258
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
-6,387
Closed -$76K
OMGA
3259
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
-15,329
Closed -$96K
VIRX
3260
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
-38,693
Closed -$184K
VINC
3261
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
-665
Closed -$53K
GATO
3262
DELISTED
Gatos Silver, Inc.
GATO
-46,688
Closed -$202K
PSTX
3263
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
-34,064
Closed -$153K
ITI
3264
DELISTED
Iteris, Inc.
ITI
-35,455
Closed -$106K
GRTS
3265
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
-56,865
Closed -$234K
SEEL
3266
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
-16
Closed -$50K
GTHX
3267
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
-47,109
Closed -$358K
TLIS
3268
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
-760
Closed -$16K
ASXC
3269
DELISTED
Asensus Surgical, Inc.
ASXC
-218,056
Closed -$137K
NEXI
3270
DELISTED
NexImmune, Inc. Common Stock
NEXI
-560
Closed -$59K
DMTK
3271
DELISTED
DermTech, Inc. Common Stock
DMTK
-25,571
Closed -$375K
MRNS
3272
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
-37,114
Closed -$347K
TAST
3273
DELISTED
Carrols Restaurant Group, Inc.
TAST
-44,035
Closed -$100K
TRVN
3274
DELISTED
Trevena, Inc.
TRVN
-231
Closed -$79K
AWH
3275
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
-4,473
Closed -$70K

Similar funds

RhumbLine Advisers's Q2 2022 Portfolio in Review

As of Q2 2022, RhumbLine Advisers held 3,375 positions worth $68.5B, down 12% from $77.7B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

RhumbLine Advisers deployed $4.06B of net new capital in Q2 2022, opening 359 new positions and adding to 2,434 existing holdings. Its largest new stake was Aspen Technology Inc: 81,883 shares worth $15M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was AT&T, an estimated $61.6M trimmed.

  • RhumbLine Advisers's largest Q2 2022 buy was Aspen Technology Inc: 81,883 shares worth $15M.
  • RhumbLine Advisers added most to Linde in Q2 2022, an estimated $124M increase.
  • RhumbLine Advisers's biggest Q2 2022 reduction was AT&T, cutting an estimated $61.6M.
  • RhumbLine Advisers fully exited Cerner Corp in Q2 2022, selling an estimated $50.9M.
  • RhumbLine Advisers's ten largest holdings make up 21% of its $68.5B portfolio in Q2 2022.
  • RhumbLine Advisers opened 359 new positions and closed 282 in Q2 2022.
  • RhumbLine Advisers's portfolio value fell 12% quarter-over-quarter to $68.5B.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.